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Abstract
Background and Aim: Enteral nutrition (EN) is applicable to 
adult Crohn’s disease (CD) in treating malnutrition and in in-
ducing remission – here as a less effective alternative than 
corticosteroids. The purpose of this review is to determine 
whether preoperative EN impacts postoperative complica-
tions of adult CD, either by means of nutritional or therapeu-
tic effects. Summary: A systematic review of English written 
full-text research articles published between January 1990 
and November 2017, including adult patients undergoing 
abdominal surgery for complicated CD after EN, was per-
formed. Four studies out of 22 were selected, all of which 
institutional, retrospective, case-control cohorts, one classi-
fied as “good quality” and three as “poor quality,” as rated by 
the Newcastle-Ottawa Scale. The application of inclusion 
and exclusion criteria resulted in a non-intentional absence 
of studies referring to supplemental EN among those re-
viewed. The reduced number of heterogeneous eligible 
studies impeded meta-analysis. In all studies, exclusive EN 
(EEN) was used and well tolerated, allowing to defer or even 
avoid surgery altogether, improving patients’ global state. 
The two studies with the greatest number of patients found 
preoperative EEN to be an independent factor against infec-
tious and non-infectious complications in 219 patients and 
against anastomotic leaks or abscesses in 38 patients. Also, 
in univariate analysis, EEN was found to increase preop-
erative immunosuppressant-free intervals and to protect 
against anastomotic dehiscences, intra-abdominal abscess-
es, surgical wound infections, ileus, stomas, and reopera-
tions in the largest study; in another study it was related to 
fewer intra-abdominal septic complications. Key Messages: 
All reviewed studies are retrospective and, consequently, of 
limited relevance. Nonetheless, all of them call the attention 
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of the scientific community to the potential benefits of pre-
operative EEN on postoperative outcomes in adult CD, call-
ing for prospective multi-institutional studies and random-
ized controlled trials. © 2018 Sociedade Portuguesa de Gastrenterologia 
Published by S. Karger AG, Basel
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Resumo
Introdução e objetivo: No adulto com doença de Crohn 
(DC) a nutrição entérica (NE) é aplicável como terapêutica 
da desnutrição ou como alternativa, menos eficaz, aos 
corticoides, para indução de remissão. O objetivo desta 
revisão é determinar se a NE pré-operatória tem impacto 
nas complicações pós-operatórias, seja pelo efeito nutri-
cional seja pelo terapêutico. Sumário: Foi realizada uma 
revisão sistemática dos artigos de investigação que in-
cluíssem doentes adultos submetidos a cirurgia abdomi-
nal por DC complicada, após NE, redigidos em inglês e 
publicados entre janeiro de 1990 e novembro de 2017. De 
22 estudos foram selecionados quatro institucionais e ret-
rospetivos de coorte, um de “fraca qualidade” e três de 
“pobre qualidade” pela “Newcastle-Ottawa Scale”. Nos es-
tudos revistos foi utilizada NE exclusiva (NEE) já que, não 
intencionalmente, os estudos com NE suplementar reuni-
ram critérios de exclusão. O pequeno número e a hetero-
geneidade dos estudos elegíveis impossibilitaram uma 
meta-análise. A NEE foi utilizada e bem tolerada em todos 
os estudos, e permitiu melhorar o estado global dos doen-
tes e protelar ou mesmo evitar a cirurgia. Nos dois estudos 
com maior número de doentes, a NEE pré-operatória foi 
um fator independente contra deiscências de sutura e ab-
cessos em 219 doentes, e contra complicações infeciosas 
intra-abdominais em 38. Em análise univariada também 
se verificou que, no maior estudo, a NEE aumentou o in-
tervalo pré-operatório livre de imunossupressores e foi 
protetora contra deiscências anastomóticas, abscessos 
intra-abdominais, infeções da ferida operatória, ileus, es-
tomas e reoperações; noutro estudo menores correla-
cionou-se com menos complicações infeciosas intra-ab-
dominais. Mensagens-chave: Todos os estudos revistos 
são retrospetivos e, consequentemente, de relevância 
limitada. No entanto, todos chamam a atenção da comu-
nidade científica para os potenciais benefícios da NEE pré-
operatória nos resultados pós-operatórios dos adultos 
com DC e para a necessidade de estudos prospetivos 
multi-institucionais e de ensaios clínicos randomizados.
© 2018 Sociedade Portuguesa de Gastrenterologia 
Publicado por S. Karger AG, Basel
Introduction
Up to 50% of Crohn’s disease (CD) patients have been 
classically described to require surgery within 10 years 
after diagnosis [1]. More recently, according to a popula-
tion-based cohort study from Denmark, the 9-year cu-
mulative risk of surgery has been reduced from 50% 
(1979–1986) to 23.3% (2003–2011), along with an in-
creased use of thiopurines and TNFα inhibitors [2]. The 
same trend was found in a similar study from Sweden – 
the risk of surgery at 5 years fell from 65.8% (1963–1975) 
to 34.6% (1991–2005) [3].
Rates of postoperative complications and stoma cre-
ation after abdominal surgery are influenced by a number 
of factors, both clinical and therapeutic, and vary widely 
across published series [4, 5]. Intra-abdominal septic 
complications (IASCs) may reach 50%, the risk factors for 
which the literature mostly reports therapy with cortico-
steroids (CSTs), malnutrition, intra-abdominal abscesses, 
low serum albumin levels, and emergent surgery [6–11].
Among medications used in the treatment of CD, CSTs 
are the one most consensual risk factor for anastomotic 
complications and, in some series, for global morbidity [4, 
6, 9, 10]. As to purine analogues, there is no evidence they 
might increase the risk of postoperative complications [9, 
11, 12]. Differently, TNFα inhibitors increase infectious 
and global surgical morbidity [11, 13–15].
In what concerns preoperative malnutrition, under-
nourished CD patients should receive perioperative nu-
tritional support, as in other pathologies of the digestive 
tract, even if this requires postponing surgery. The en-
teric route is preferred, whereas parenteral nutrition (PN) 
is only indicated when the digestive tract is insufficient or 
unavailable [16–19]. Whenever the digestive tract does 
not provide enough calories – in patients who tolerate 
enteral nutrition (EN) but in insufficient quantities – the 
use of total or supplementary PN becomes inevitable [16]; 
operating undernourished patients, with consequent in-
creases in postoperative complications and stomas, is to 
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be avoided. Interestingly, there are some early pioneer 
studies that have found potential advantages in the appli-
cation of EN to malnourished patients, in whom they 
seem to produce better surgical results [20, 21].
Concerning therapy with CSTs, exclusive EN (EEN) 
has largely substituted prednisolone as first-line remis-
sion-inducing therapy for moderate to severe disease 
flares in children [22, 23]. In striking opposition, the for-
mer remain the mainstay of therapy for these situations 
in adults, in whom they seem more effective over EEN 
[24–26]. In this age group, the therapeutic value of EN in 
CD is controversial outside the bounds of malnutrition. 
It may therefore be advised as remission-inducing thera-
py in case of refusal or intolerance to CSTs, in mild exten-
sive small bowel disease (here as primary or as adjuvant 
therapy), and as adjuvant therapy in the undernourished 
which maintain inflammatory stenosis, despite maxi-
mized adequate pharmacological therapy [24, 27–29]. 
The grade of evidence concerning the superiority of CSTs 
over EEN in adult patients is, however, of very low qual-
ity [24].
The mechanisms by which EEN induces remission of 
CD are not well established [29]. A number of studies 
suggest that EN promotes the balancing of mucosal cyto-
kines – by decreasing those which are pro-inflammatory 
[30, 31], restores mucosal integrity and its barrier func-
tion [24, 30, 32], decreases adjacent mesenteric fat inflam-
mation [33, 34], and alters the composition of the intesti-
nal microbiome [35, 36]. It is possible that bowel rest and 
interruption of exposure to alimentary and some bacte-
rial allergens may be contributing mechanisms [29].
Aim
To determine whether preoperative EN impacts post-
operative complications of adult CD, either by means of 
nutritional or therapeutic effects.
Methods
A systematic review of research articles including the use of 
preoperative EN in adults with CD submitted to abdominal sur-
gery, from January 1990 to November 2017, was conducted.
An initial search was carried out through PubMed-MEDLINE, 
ScienceDirect, and Google Scholar. Medical subject headings 
(MeSH) applied were the following:
 − for PubMed-MEDLINE, “Crohn’s disease” AND “surgery” 
AND “postoperative” AND “complications” AND “adults” 
AND “preoperative” AND “enteral nutrition” AND “not re-
view”; filters applied were “full text,” “English,” and “humans”;
 − for ScienceDirect, “Crohn’s disease” and “enteral nutrition” 
(Title, abstract, keywords);
 − for Google Scholar, “Crohn’s disease and preoperative enteral 
nutrition and adults.”
Two further searches were conducted:
 − upon references of all articles selected as eligible, as result of the 
initial search;
 − of “similar articles” of the two most recent studies of those al-
ready selected as eligible.
Methodology respected Preferred Reporting Items for System-
atic reviews and Meta-Analyses (PRISMA) recommendations 
[37].
Screening and testing for eligibility were performed upon Eng-
lish written abstracts. A grid was constructed to assess articles for 
eligibility and select them for inclusion, according to specific inclu-
sion and exclusion criteria.
Inclusion criteria:
 − Original clinical research articles wherein preoperative EN was 
administered to adult CD patients operated on for intestinal 
complications, as long as EN impact on postoperative compli-
cations is discriminated.
 − English full-text articles published in peer-reviewed journals, 
including those published online ahead of print, within the 
time frame considered.
 − Retrospective and prospective studies, whether cohort, case se-
ries, case control, or randomized controlled trials, regardless of 
aims and number of patients.
 − Studies concerning adults – patients considered adults by the 
authors of the study were similarly assumed.
 − All formulas, means of administration, and regimens of EN – 
exclusive or supplemental, as complement to PN or a conven-
tional diet.
 − Data referring to each type of nutritional regimen is accord-
ingly discriminated and treated separately from that respecting 
patients and impact on postoperative morbidity.
 − Paucity or even absence of data regarding repercussions of EN 
on patients’ preoperative state will not be criterion for exclu-
sion.
Exclusion criteria:
 − Review articles (both systematic and non-systematic), case re-
ports, comments, letters, and book chapters.
 − Abstracts of conferences, oral presentations, and posters pre-
sented in meetings.
 − Papers concerning children or adolescents or whose authors 
belonged to pediatric institutions.
 − Patient overlap among articles – the article containing the most 
patients was selected.
 − Articles or results referring to the analysis of postoperative re-
currence of CD.
 − Absence of separate data concerning CD patients as opposed to 
those with ulcerative, undetermined, and unclassified colitis.
The quality of the studies was rated by awarding stars in each 
domain following the guidelines of the Newcastle-Ottawa Scale 
(NOS) [38].
Two authors (A.R. and I.B.) undertook the bibliographic 
search, independently screened the articles for eligibility, and as-
sessed them thoroughly for inclusion. Discussion took place until 
consensus was reached whenever accordance was not met initial-
ly. Three authors (A.R., I.B., and P.L.) reviewed the included ar-
ticles.
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Results
One hundred and ninety-six references were identified 
in PubMed-MEDLINE, 61 in ScienceDirect, 4,880 in 
Google Scholar, and 157 through secondary search 
(Fig. 1). After the irrelevant titles and duplicates were re-
moved, 257 records were screened, 22 of which were eli-
gible. Of these, one had no English abstract [39] and three 
had no English full text [40–42]. The main features of the 
14 full-text excluded articles are summarized in Table 1 
[43–56] – eight of them had no separate results on differ-
ent nutritional regimens or on treated patients [44, 47–
50, 52–54] and four had no data on EN regimen [43, 45, 
55, 56]; two other articles [46, 51] met the inclusion cri-
teria but overlapped patients with a third study which 
contained a larger number of patients and was therefore 
detrimentally included. All studies in which supplemen-
tal EN was used with conventional diet or with PN did not 
meet the inclusion criteria.
The main characteristics of the four articles selected 
for review [57–60] are summarized in Tables 2–5. Table 
2 refers to the general characteristics, aims, methods, in-
dications for and information concerning preoperative 
EEN regimen, and main conclusions of the articles under 
review. Table 3 discriminates the characteristics of oper-
ated patient groups, the variables studied in each, studies’ 
limitations, and the NOS quality assessment – criteria for 
which, as applied to cohort studies, being presented as 
online supplementary material (for all online suppl. 
material, see www.karger.com/doi/10.1159/000494674) 
[38]. In Tables 4 and 5, the impact of preoperative EEN 
on clinical and surgical outcomes is detailed. No mortal-
ity was reported. Relevant data from these trials not ex-
pressed in the tables will be detailed below.
Li et al. [57] analyzed risk factors for postoperative 
complications after classifying 708 surgeries into four 
groups according to patients’ preoperative management 
(Table 3). EEN was associated with a longer immunosup-
Records identified
through
PubMed-MEDLINE
(n = 196)
Total
(n = 5,294)
Records identified through
secondary searches
• “similar articles” (n = 138)
• references (n = 19)
Records identified
through
ScienceDirect
(n = 61)
Records after removal of
duplicates and irrelevant titles
(n = 257)
Articles assessed for
eligibility
(n = 22)
Records identified
through
Google Scholar
(n = 4,880)
Records excluded (n = 235)
Records excluded (n = 4)
• No English abstract (n = 1)
• No English full text (n = 3)
Excluded articles (n = 14)
• Patients overlap with a
   larger study (n = 2)
• No data concerning EN
 regimen (n = 4) or separate
 results concerning different
 applied nutritional
 regimens (n = 8)
Records screened
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Included articles
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Fig. 1. Study selection process. EN, enteral 
nutrition.
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Table 1. Main features and criteria justifying exclusion of review candidate full-text articles
Authors,
country and
year of
publication
Main cause of
exclusion
Study
design
Time
frame
Aims Total CD pts/
number of
preoperative
AN CD pts
Main results
Smedh et al. [43], 
Sweden,
2002
No data on EN formu-
lation and on EEN-
treated pts
Pro-
spective
01-1996
to
01-2000
To find differences in post-op 
results between sutured and 
stapled anastomoses in CD 
intestinal resections
42 CD/21 EEN Pre-op EEN, percutaneous drainage of abscesses, 
and weaning of CSTs, not the anastomotic tech-
nique, may have been decisive in the low post-op 
morbidity achieved
Zerbib et al. [44], 
France,
2010
Small number of 
EN-treated pts and no 
separate results on EN 
and TPN pts
Retro-
spective
12-1997
to
01-2007
To evaluate the effect of pre-op 
treatment of sepsis and malnutri-
tion and of drug withdrawal on 
post-op complications of pen-
etrating CD
78 CD/5 EN,
45 TPN
In pts treated with pre-op AN, BMI ≤20 and 
serum albumin ≤3.0 mg/L were not risk factors for 
post-op complications; pts’ pre-op management 
led to low post-op morbidity and a low stoma rate
Kanazawa et al. 
[45], Japan,
2012
No data on EN regi-
men and on treated pts
Retro-
spective
01-2005
to
12-2010
To identify pre-op risk factors in 
CD pts for post-op IASCs
633 CD/325 EN Penetrating CD, operating time >180 min, and 
hand-sewn anastomosis were independent risk 
factors for IASCs
Li et al. [46],
China, 2014* Eligible for inclusion but pt overlap with a 
larger study
Retro-
spective
02-2001
to
04-2011
To assess the effect of pre-op EEN 
on 3-month post-op IASCs in CD 
pts with en terocutaneous fistula
123 CD/55 EEN Pre-op EEN and age >35 years were independent 
protective factors against 3-month post-op IASCs
Zhu et al. [47], 
China, 2015* No separate data or results on EEN-, 
PN+EN-, and TPN-
treated pts
RCT 11-2011
to
12-2013
To assess whether the best pre-op 
AN goal is nutritional improve-
ment or decreased CD activity
91 CD/78 EEN,
8 PN+EN,
5 TPN
Decrease in CD activity and nutritional improve-
ment had similar surgical outcomes, but the first 
was achieved faster
Zhang et al. [48], 
China,
2015* Limited data on EN regimen and no sepa-rate data on EN- and 
PN-treated pts
Retro-
spective
04-2010
to
04-2014 
To assess whether penetrating CD 
with or without intra-abdominal 
sepsis is a risk factor for post-op 
complications
288 CD/190 EN,
25 PN
Penetrating CD with abscesses was an indepen-
dent risk factor for post-op complications; pre-op 
EN and serum albumin >3.5 mg/L were protective 
factors
Zhang et al. [49], 
China,
2015
No separate data or 
results on EEN-, 
PN+EN-, and TPN-
treated pts
Retro-
spective
03-2008
to
05-2014
To evaluate the influence of 
pre-op BMI and serum albumin 
on IASCs in CD pts
64 CD/13 EEN,
15 PN+EN,
4 TPN
Pre-op BMI was a better nutritional indicator for 
IASCs than pre-op serum albumin
Guo et al. 
[50], China, 
2016* No separate data or results on EEN-, PN+EN-, and TPN-
treated pts
Retro-
spective
Not
reported
(paper
accepted
08-2015)
To evaluate whether pre-op 
nutritional therapy in CD can 
reduce the risk of anastomotic 
dehiscence
123 CD/48 EEN,
6 PN+EN,
3 TPN
Pre-op nutritional support and serum albumin 
>3.5 mg/L were independent protective factors 
against anastomotic leakage and primary stomata
Wang et al. [51], 
China,
2016* Eligible for inclusion but pt overlap with a larger study Retro-spective 01-2011to12-2012 To assess the value of pre-op EEN on post-op complications and CD recurrence rate 81 CD/42 EEN Pre-op EEN for 4 weeks significantly increased serum albumin, prealbumin, and hemoglobin, improved pts’ inflammatory status, and decreased 
infectious and non-infectious post-op complica-
tions
Guo et al. 
[52], China, 
2017* No separate data or results for pts treated with EN or PN fol-
lowed by EN
Retro-
spective
01-2013
to
01-2015
To assess risk factors for SSI in 
CD pts with gastrointestinal 
fistulae
118 CD/118 EN
(29 < and 89 >3
months), 79 PN
followed by EN
Pre-op EN <3 months, anemia, and bacteria in 
fistula tract were independent risk factors for SSI; 
percutaneous abscess drainage was a protective 
factor
Dreznik et al. 
[53], Israel,
2017
No separate data or 
results on EN-, 
EN+PN-, and TPN-
treated pts
Retro-
spective
01-2008
to
12-2014
To evaluate if pre-op nutritional 
support in CD can reduce post-op 
complications
87 CD/14 EN,
17 TPN,
6 PN+EN
No difference found in 30-day post-op complica-
tions between two groups of pts – with and with-
out pre-op nutritional support – but first group 
had a significantly lower readmission rate
Liu et al. [54], 
China, 2017* No separate data or results on EN- and 
PN-treated pts
Retro-
spective
01-2014
to
12-2016
To assess risk factors for post-op 
SSI after CD bowel resection with 
anastomosis
154 CD/141 EN,
104 PN±EN
Low pre-op prealbumin, longer duration of 
surgery, and elevated intraoperative lactates were 
independent risk factors for SSI
Fumery et al. 
[55], France,
2017
No data on EN regi-
men or on EN- and 
PN-treated pts
Pro-
spective
nation-
wide
09-2010
to
08-2014
To assess frequency and risk 
factors for 30-day morbidity after 
ileocecal resection in CD pts
209 CD/32 EN,
30 PN
Four-week CST therapy was an independent risk 
factor for post-op complications
2015 ESCP
Collaborating 
Group [56],
2017
No data on EN regi-
men or on EN- and 
PN-treated pts
Interna-
tional pro-
spective
snapshot
audit
01-2015
to
03-2015
To evaluate pre- and intra-
operative risk factors on 30-day 
post-op results after hemicolec-
tomy and ileocecal resection for 
CD
375 CD/40 EN,
32 PN
Pre-op PN, surgery within 2 weeks, and un-
planned intraoperative events were independent 
risk factors for post-op complications
CD, Crohn’s disease; pt(s), patient(s); AN, artificial nutrition; EN, enteral nutrition; EEN, exclusive enteral nutrition; post-op, postoperative; pre-op, preoperative; CST, corticosteroid; 
TPN, total parenteral nutrition; BMI, body mass index; IASCs, intraabdominal septic complications; PN, parenteral nutrition; RCT, randomized controlled trial; SSI, surgical site 
infections; ESCP, European Society of Coloproctology. * These papers were produced at the same Chinese institution as the one which produced the article by Li et al. [57] (Department 
of General Surgery, Jinling Hospital, Medical School of Nanjing University, Nanjing, PR China), with collected data within overlapping periods of time (01-2001 to 03-2014).
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pressant-free interval and fewer emergent surgeries, pri-
mary stomata, anastomotic leaks, intra-abdominal ab-
scesses, wound infections, ileus, and reoperations on uni-
variate analysis (Tables 4, 5). The authors identified EEN 
as an independent protective factor against postoperative 
complications (both infectious and non-infectious). Pre-
operative immunosuppressive therapy, perforation or 
abscess, emergent surgery, previous surgery for CD, and 
older age were independent risk factors for infectious 
complications (Table 5). The first two risk factors and 
longer operative time were the independent risk factors 
identified for non-infectious complications. The authors 
argued that the prospective nature of the database and the 
cohort nature of this study may have mitigated some of 
the limitations and biases inherent to retrospective stud-
ies.
Heerasing et al. [58] retrospectively revised 51 patients 
treated with preoperative EEN after nutritional assess-
ment. Thirteen patients (25%) ended up not requiring 
surgery. For each of the 38 operated EEN patients, two 
matched non-EEN controls were sought (Table 2). The 
latter were found to have higher basal body mass index 
(BMI), lower basal C-reactive protein (CRP) values and 
lower prevalence of treatment with antibiotics (Table 3). 
EEN was found to be an independent factor against anas-
tomotic leaks and/or abscesses and led to significantly 
lower global postoperative morbidity and shorter opera-
tive times (Tables 4, 5). Patients with IASCs had signifi-
Table 2. Characteristics, aims, methods, indications for and data regarding preoperative exclusive enteral nutrition, and main conclu-
sions of the articles under review
Authors,
country,
and year
of publi-
cation
Study
design
and time
frame
Pro-
spec-
tive
data
base
Aims Inclusion
criteria
Indications
for pre-op
EEN
EEN/
no-EEN
patients, n
Type of
EEN
Duration 
of EEN
Route of
adminis-
tration
Tolerance
to EEN
Main results
Li et al. [57], 
China,
2015
Retro
spective
cohort
(01-2001
to
03-2014)
Yes To evaluate the effect 
of pre-op EEN on 
30-day post-op 
outcomes in CD pts
Abdominal
surgery
Withdrawal
of immuno-
suppression
219/561 Elemental* Up to 8 
weeks
NGT Yes Pre-op EEN was an 
independent protective 
factor against post-op 
infectious and non-infec-
tious complications, 
significantly increased the 
drug-free interval, and 
decreased the emergent 
surgery, stoma, anasto-
motic leak, and reopera-
tion rates
Heerasing
et al. [58], 
UK, 2017
Retro-
spective
cohort
(2008
to
2015)
No To evaluate if pre-op 
EEN could provide a 
bridge to surgery to 
reduce post-op 
complications and 
CD recurrence rate
Stricturing
and pene-
trating com-
plications
Dietitian
prescription
38/76 Polymeric
TGF-β2
enriched†
6.3 weeks 
(mean)
PO Yes Pre-op EEN led to less 
inflammation and shorter 
operative time, protected 
against anastomotic leak 
and/or abscesses, and 
even avoided surgery in 
some pts
Beaupel
et al. [59],
France,
2017
Retro-
spective
cohort
(06-2011
to
03-2015)
Yes To assess whether 
EEN enriched with 
TGF-β2 could reduce 
30-day post-op 
complications after 
surgery in high-risk§ 
CD pts
Elective
ileocecal or
ileocolic
resection
High-risk§
pts
35§/21 Polymeric
TGF-β2
enriched†
21.6 days 
(median)
PO – 
34 pts;
NGT – 
1 pt
All but
1 pt
No prognostic factors for 
post-op global and 
abdominal complications 
identified; TGF-β2-
enriched EEN could limit 
the deleterious effects of 
high-risk factors for 
post-op complications
Zhu et al. 
[60], 
China,
2017
Retro-
spective
cohort
(01-2011
to
06-2015)
No To assess the value of 
EEN on 2-year 
surgery rate and on 
30-day post-op 
morbidity in pts with 
percutaneously 
undrainable >1 cm 
intra-abdominal 
abscesses
Recurrent
or not
improving
abscesses,
and/or
fistulae
and/or
bowel
obstruction
Compliance/
tolerance to
EEN
46/28 Elemental* 39 days 
(median)
NGT Yes Pre-op EEN was an 
independent factor 
against surgery and 
significantly increased 
serum albumin, improved 
pts’ inflammatory status, 
decreased IASCs, and led 
to a shorter post-op 
hospitalization
pre-op, preoperative; EEN, exclusive enteral nutrition; pt(s), patient(s); post-op, postoperative; CD, Crohn’s disease; NGT, nasogastric tube; TGF-β2, transforming growth factor 
beta-2; PO, per os; IASCs, intraabdominal septic complications. * Peptisorb Liquid® (Nutricia, Amsterdam, The Netherlands) – semi-elemental, 17.6 g carbohydrates, 1.7 g lipids, and 
4 g protein/100 mL, 1 kcal/mL. † Modulen IBD® (Nestlé, Vevey, Switzerland) – polymeric TGF-β2 enriched, 54 g carbohydrates, 23 g lipids, and 18 g protein/100 mL, 1 kcal/mL. § High-
risk patients: obstructive symptoms and/or penetrating CD and/or corticosteroid therapy and/or weight loss >10%.
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Table 3. Characteristics of operated patient groups, variables studied, and limitations of each reviewed article
Authors Sur-
geries,
n
EEN pts,
n
No-EEN pts,
n
Variables similar between study
groups
Variables significantly
different between
groups
Study limitations Newcastle-
Ottawa
score
Li et al.
[57]
780 219 –
group 4* 332 – group 1†29 – group 2‡
128 – group 3§
Pt gender and age at diagnosis and surgery, BMI, previ-
ous CD surgeries, disease duration, location and behav-
ior, perforation/abscess, preoperative CSTs, immuno-
modulatory and anti-TNF treatment (compared with 
groups 2‡ and 3§), surgical indication, approach and 
main procedure, operative time, and blood loss; groups 
were not matched
Group 4* had > 
drug-free interval than 
groups 2‡ and 3§, at 
surgery
Retrospective study; no sample size 
calculation; pts with digestive 
intolerance may be sicker than 
EEN pts
Poor
quality
Heerasing
et al. [58]
114 38 76 – straight
to surgery
Pt ethnicity, gender, age, smoking status and comorbid-
ities, previous surgeries, CD duration, Montreal classifi-
cation, abscesses, weight, preoperative serum albumin, 
CSTs, immunomodulatory and anti-TNF treatment, 
and surgical indication and approach; groups were 
matched for age at diagnosis, disease duration and 
behavior, and type of surgery
EEN pts had < BMI 
and > baseline disease 
activity and CRP, and 
more often ATB at 
surgery
Retrospective data collection; small 
sample size; missing data on CD 
course and severity; incomplete 
matching of groups
Fair
quality
Beaupel
et al. [59]
56 35 high-
riskII
21 low-risk
– straight to
surgery
Pt gender, age, smoking status, BMI, CD duration, 
perianal lesions and previous intestinal resection, serum 
albumin, immunomodulatory and biologic therapy, 
type of surgery and approach, anastomotic technique, 
and intraoperative findings; groups were not matched
High-risk EEN pts had 
> rate of obstructive 
symptoms and/or 
weight loss >10% and/
or penetrating CD 
and/or CST therapy 
and > CD intractability
Retrospective study; small sample 
size; no control groups with 
different nutritional support; 
biased prescription
Poor
quality
Zhu et al.
[60]
74 46 28 – intolerant
or noncompli-
ant with EEN
Pt gender, HGB and WBC, previous surgeries, CD 
location and behavior, perianal lesions, CSTs, immuno-
modulatory and anti-TNF treatment at time of abscess 
diagnosis, abscess location, number of abscesses >3 cm, 
surgical approach, operative time, and intraoperative 
blood loss; groups were not matched
EEN pts had > serum 
albumin and < ESR 
and CRP at surgery
Retrospective study; small sample 
size; withdrawal of EEN before 
surgery in some pts and initiation 
of immunomodulatory or biologi-
cal therapy after abscess resolution 
also before surgery, in others
Poor
quality
EEN, exclusive enteral nutrition; pt(s), patient(s); BMI, body mass index; CD, Crohn’s disease; CST, corticosteroid; >, higher; <, lower; CRP, C-reactive protein; ATB, antibiotic; 
HGB, hemoglobin; WBC, white blood cells; ESR, erythrocyte sedimentation rate. * Group 4 – preoperative EEN and immunosuppressant-free interval (CSTs, immunomodulators, and 
biologics) less than 8 weeks. † Group 1 – without preoperative immunosuppressant therapy within 8 weeks of surgery. ‡ Group 2 – immunosuppressant therapy at surgery. § Group 3 
– preoperative immunosuppressant-free interval less than 8 weeks. II High-risk patients: obstructive symptoms and/or penetrating CD and/or CST therapy and/or weight loss >10%. 
Criteria for application of the Newcastle-Ottawa Quality Assessment Scale to cohort studies are detailed in the supplementary material (Table 6). 
Table 4. Impact of preoperative exclusive enteral nutrition on clinical outcomes and operative data
Authors; 
EEN/no-
EEN pa-
tients, n
Medication
withdrawal
Uni-
variate
analysis, p
Clinical
impact
Uni-
variate
analysis, p
Impact on serum
variables
Univariate
analysis, p
Emergent
surgery, %
Uni-
variate
analysis, p
Operative time, 
min
Uni-
variate
analy sis, 
p
Li et al.
[57];
219*/332†,
29‡, 128§
Group 4* had
> drug-free
interval than
groups 2† and 3‡
<0.001 Group 4 had
>↑ in BMI
than groups
1§ and 3
0.003§,
0.03‡
N/A – Group 4 – 6.4
Group 2 – 51.7
Group 3 – 20.3
<0.001‡,
<0.05§
Group 4 – 122
Group 1 – 132
Group 2 – 140
Group 3 – 129
ns
Heerasing
et al. [58];
38/76
No – No (weight
and BMI)
ns >↓ in CRP 0.02 N/R – EEN 3 h vs.
no-EEN
patients 3.5 h
<0.001
Beaupel
et al. [59];
35/21
CSTs – 62.5%
of patients
– No (weight
loss >10%,
BMI, and
complicated
CD)
ns >↑ in albumin
and >↓ in ESR
and CRP
<0.05 and
<0.001
N/A – N/R –
Zhu et al.
[60];
46/28
N/R – N/R – >↑ in albumin
and >↓ in CRP
and ESR
<0.05/<0.001
and
<0.001/<0.001
and <0.001
N/A – EEN 204 vs.
no-EEN
patients
198
ns
EEN, exclusive enteral nutrition; >, higher; ↑, increase; BMI, body mass index; N/A, not available; ↓, decrease; CRP, C-reactive protein; N/R, not reported; CST, corticosteroid; CD, 
Crohn’s disease; <, lower; ESR, erythrocyte sedimentation rate. * Group 4 – preoperative EEN and immunosuppressant-free interval (CSTs, immunomodulators, and biologics) less 
than 8 weeks. †  Group 2 – immunosuppressant therapy at surgery. ‡  Group 3 – preoperative immunosuppressant-free interval less than 8 weeks. §  Group 1 – preoperative 
immunosuppressant-free interval more than 8 weeks.
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cantly longer lengths of hospital stay and a higher read-
mission rate. The authors point out some limitations to 
this study such as missing data on medical records and 
incomplete matching of disease severity. Also, they did 
not clarify the reasons why control-matched patients did 
not receive nutritional support – it may even have been 
due to the baseline differences in BMI and/or serum CRP 
levels, but this was not mentioned.
Beaupel et al. [59] compared two groups of patients, 21 
“low-risk” versus 35 “high-risk” for postoperative com-
plications, distinct regarding CD behavior, severity and 
complications, nutritional state, and CST treatment (Ta-
bles 2, 3). As the rate of postoperative complications, for 
which no protective or risk factors were identified, was 
not statistically different between the two groups (Table 
5), the authors admitted this indicated that TGF-β2-
enriched EEN was beneficial for high-risk CD patients 
(Table 2).
In the study published by Zhu et al. [60], 54 of 83 CD 
patients were treated with EEN for abdominal abscesses 
not amenable to percutaneous drainage, either until ab-
scess resolution or until surgery (from 7 to 1,000 days). 
The remaining 29 patients did not tolerate or comply with 
EEN and had a significantly higher cumulative 1-year 
surgical rate than EEN patients. EEN led to a higher rate 
of abscess resolution and was an independent protective 
factor against surgery. Previous abdominal surgery and 
abscess diameter > 3 cm were independent risk factors for 
surgery. Patients’ nutritional status was not mentioned. 
Forty-six EEN-treated and 28 EEN-untreated patients re-
quired surgery, the former having significantly fewer 
postoperative IASCs (Tables 2, 5). The authors noted lim-
itations to the study beyond its retrospective nature and 
reduced number of patients: some of the latter suspended 
EEN and/or restarted immunosuppressants after abscess 
resolution, for unclarified periods of time.
In all studies, preoperative EEN was well tolerated by 
adults with complicated CD and a patent intestinal route 
– 338 out of 1,024 operated patients received preopera-
tive EEN. Compared to their respective controls, pa-
tients under preoperative EEN achieved significantly 
lower levels of preoperative inflammatory markers in 
three of the reviewed studies [58–60], in two of which 
with concomitant increases in serum albumin values 
[59, 60]. The two studies with the greatest number of 
patients found preoperative EEN to be an independent 
factor against postoperative infectious and non-infec-
tious complications [57] and against anastomotic leaks 
or abscesses [58].
However, quality grading for risk of bias according to 
NOS criteria [38] (Table 3) qualifies only one of the stud-
ies as “fair quality” [58] – the only one to match compared 
patient groups. The remaining studies were considered 
“poor quality,” essentially for not scoring in the compa-
rability domain (see online suppl. material).
Table 5. Impact of preoperative exclusive enteral nutrition on surgical outcomes
Authors EEN/no-
EEN pa-
tients, n
Morbidity, % Uni-
variate
analysis, 
p
Multivariate
analysis
Anastomotic
leak, %
Uni-
variate
analysis, p
Stoma rate, % Uni-
variate
analy sis, 
pEEN patients no-EEN patients EEN
patients
no-EEN
patients
EEN
patients
no-EEN 
patients
Li et al.
[57]
219*/332†,
29‡, 128§
Infectious
– 18.7*/
non-infectious
– 7.8*
Infectious
– 51.7‡, 28.9†/
non-infectious
– 31†, 15.6‡
<0001/
<0.001
OR – 0.53II/
OR – 0.35II 
4.1* 17.2†
10.2‡
3§
<0.05†
<0.05‡
ns§
17.8* 65.5†
34.4‡
22§
<0.001†
<0.05‡
ns§
Heerasing
et al. [58]
38/76 Global – 8/
anastomotic
leak or abscesses
– 3
Global – 32/
anastomotic
leak or abscess
– 20
<0.001/
0.019
–/OR – 9.1** N/R N/R – 3 8 ns
Beaupel
et al. [59]
35/21 Global – 22.9/
ASCs – 14.3
Global – 23.8/
ASCs – 23.8
ns – 2.8 0 ns 11.4 0 ns
Zhu et al.
[60]
46/28 IASCs – 6.5 IASCs – 25 0.036 – N/R N/R – 43.5 46.4 ns
EEN, exclusive enteral nutrition; OR, odds ratio; N/R, not reported; ASCs, abdominal septic complications; IASCs, intraabdominal septic complications. * Group 4 – preoperative 
EEN and immunosuppressant-free interval (CSTs, immunomodulators, and biologics) less than 8 weeks. † Group 2 – immunosuppressant therapy at surgery. ‡ Group 3 – preoperative 
immunosuppressant-free interval less than 8 weeks. § Group 1 – preoperative immunosuppressant-free interval more than 8 weeks. II OR – likelihood of EEN patients having infectious 
and non-infectious complications, respectively. ** OR – likelihood of EEN patients not having anastomotic dehiscence or abscess.
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Discussion
All reviewed articles were institutional retrospective 
cohort studies with heterogeneous methods and inclu-
sion criteria. Patients received preoperative EEN with dif-
ferent indications and regimens and for different periods 
of time. Those belonging to control groups were also het-
erogeneous between studies and even within the same 
study, namely regarding baseline nutritional state and 
CD activity, behavior, and medication. The type of post-
operative complications analyzed also varied between 
studies. Meta-analysis was not done due to the small 
number of studies with varying designs, posing issues 
over the estimation of the between-study variance [61].
A non-intentional absence of studies referring to sup-
plemental EN among those reviewed resulted from those 
which were eligible and referring to supplemental EN 
meeting exclusion criteria [44, 45, 47–50, 52–56].
From the reviewed articles, two were from China [57, 
60], one of them being the study with the largest number 
of patients [57]. This latter study contains more patients 
than the sum of all three other reviewed papers, possibly 
raising transferability issues to other institutions and 
countries, namely, the Western ones. Although EN is not 
indicated as treatment for CD in adults by Chinese guide-
lines [62], eight of the excluded studies originated from 
China. The article by Li et al. [57] was produced by the 
same institution as that of seven [46–48, 50–52, 54] of the 
previous 8 studies, the latter being well known for its pub-
lications regarding this topic [31, 34, 63]. One of the ex-
cluded articles is Japanese [45]. The Japanese consensus 
indicates EN for remission induction and maintenance in 
adult CD [64] but, for the most part, studies from Japan 
focus on the possible impact of this nutrition on the re-
duction of postoperative relapse and remission mainte-
nance – both as monotherapy and as an adjunct to phar-
macotherapy [65–67].
Both reviewed Western studies made use of orally ad-
ministered polymeric EEN [58, 59]. In both cases, an en-
riched formula with transforming growth factor beta-2 
(TGF-β2) was used, the advantages of which have been 
studied for this pathology but not yet proved [17, 24, 68]. 
In the West, the administration of nutritional support by 
means of a nasogastric tube is poorly accepted by adults 
[24]. However, tolerance and acceptance towards the oral 
route has grown with improvements in the quality and 
variety of flavors of the polymeric formulations [24, 27].
In all studies, preoperative EEN was well tolerated by 
adults with complicated CD and a patent intestinal route, 
even in the presence of active inflammation and abdomi-
nal abscesses, leading to the possibility of postponing and 
even preventing surgery [58, 60]. A preoperative lag al-
lowed for amelioration of patient conditions – reducing 
the inflammatory environment [58–60], increasing se-
rum albumin [59, 60], weaning or suspending CST ther-
apy [57, 59], and treating abscesses [59, 60] – as opposed 
to patients operated on immediately [58, 59]. These prop-
erties have also been attributed to nutritional support, 
both enteral and parenteral, by other authors [44, 47, 48, 
50, 52–54, 69–72]. Also, in one of the reviewed studies 
[59], going straight to surgery (non-EEN patients) was an 
independent risk factor for anastomotic leaks and/or in-
tra-abdominal abscesses.
The authors of one of the reviewed studies [60] refer 
that EEN led to a significant improvement in nutritional 
status based solely on a significant rise in serum albumin. 
Three articles specify BMI values [57–59], one of which 
also referring to weight loss above 10% [59] and another 
referring to basal and preoperative weights [58]. Never-
theless, in truth, none of the papers explains the method-
ology used for nutritional assessment. Standing alone, 
these anthropometric and laboratory parameters are not 
indicators of nutritional status in the presence of an active 
inflammatory syndrome, seeing they are highly influ-
enced by variation in and retention of fluids [16, 49]. Pre-
operative serum albumin levels may reflect variations in 
a patient’s inflammatory status and/or nutritional state 
and, therefore, for one or both reasons, values below 3 g/
dL are a risk factor for postoperative complications in ab-
dominal surgery [4, 5, 7, 11, 16]. The inflammatory envi-
ronment elicited by the disease and surgery actively con-
tributes to a descent in serum albumin and perioperative 
undernutrition, the control of the former being determi-
nant in the improvement of the latter two [63, 73, 74]. In 
so being, nutritional support may be an essential weapon 
against the systemic inflammatory response syndrome 
and in promoting the restoration of the intestinal muco-
sal barrier, of immunological balance and tissue scarring, 
thereby leading to fewer postoperative complications and 
a faster recovery of the patient [16, 73, 74].
Two studies found preoperative EEN to be an inde-
pendent factor against infectious and non-infectious 
complications [57] and against anastomotic leaks or ab-
scesses [58]. However, only the study involving 780 sur-
geries [57] found EEN to lead to a significantly lower oc-
currence of postoperative emergent surgery, primary sto-
mata, anastomotic leaks, and reoperations, as opposed to 
groups under immunosuppression alone. Although anas-
tomotic dehiscence rates among the EEN and immuno-
suppressant-free groups were low (4.1 and 3%, respec-
Preoperative EN and Surgical Outcomes 
in Adults with CD
193GE Port J Gastroenterol 2019;26:184–195
DOI: 10.1159/000494674
tively), stoma rates were notably higher (17.8 and 22%, 
respectively) [57]. In the other three studies [58–60], sto-
ma rates were similar between EEN and control groups 
but, in one of them, they were in fact very high (43.5 and 
46.4%, respectively) [60].
It is noteworthy that no study reported on ostomies 
resulting from anastomotic dehiscence, on temporary os-
tomies that became permanent, or on ostomy closure 
morbidity. Yet, one of the main concerns of CD patients 
is that surgery may result in the need for an ostomy bag 
[75], which can lead to fear or even refusal of operations. 
Therefore, the possibility that preoperative EEN may lead 
to a lower stoma rate – whether primary or resulting from 
postoperative complications – is one of the most impor-
tant aspects to consider in the surgery of these patients.
Despite the fact that all reviewed studies are retrospec-
tive and, consequently, of limited relevance, there is no 
doubt EEN was well tolerated and the preferred nutri-
tional support, in the absence of intestinal obstruction, in 
the presence of complicated disease. In addition to its nu-
tritional value, however, it is necessary to ascertain wheth-
er in fact this nutritional support conduces to mitigation 
of postoperative complications, reductions in stoma 
rates, decreased disease activity, removal of harmful 
drugs, and avoidance of emergent surgery.
The studies do collectively, nonetheless, call the atten-
tion of the scientific community to the potential benefits 
of preoperative EEN on postoperative outcomes in adult 
CD. They also carry enough impact to call for multi-in-
stitutional studies and randomized controlled trials. The 
design of this kind of trials, however, is a painstaking en-
deavor, since a great number of variables – relating to 
patients, disease, medication, surgical indications, and 
technique – must be considered. Also, ethical issues con-
cerning randomization of malnourished CD patients to-
wards receiving or not receiving nutritional support be-
fore surgery may limit the feasibility of such studies.
The determination of the properties of preoperative 
EEN is of importance since, as of now, this strategy has 
been very little or not at all used in most referral centers 
worldwide, outside the bounds of nutritional support. 
Only then will the contribution of preoperative EN on 
postoperative morbidity and stoma rates of adult CD be 
defined.
Conclusions
In summary, preoperative EEN in adult CD surgery 
can be a valid option in specific situations – to improve 
nutritional status in the absence of intestinal obstruction, 
as an adjuvant to the treatment of existing abscesses and/
or fistulas, and to attempt CST suspension.
However, none of the reviewed studies clarifies the 
possible existence of a cause-effect relationship between 
preoperative EEN and surgical morbidity in adult CD, 
their conclusions being far from definite. The few existing 
studies either carry obvious biases, varying risks of sys-
tematic errors, or questionable transferability of conclu-
sions to other institutions. Prospective studies are re-
quired to establish whether or not preoperative EEN can 
in fact improve surgical outcomes in these patients.
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